Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD) are highly comorbid, yet the combined condition has not been subject to any placebo-controlled treatment trials. This study reports a trial of vortioxetine, an antidepressant that has also shown benefit in Generalized Anxiety Disorder (GAD), in patients meeting DSM-5 criteria for both MDD and SAD. METHODS: The study was a 12-week double-blind, placebo-controlled comparison of vortioxetine 10-20 mg/day or placebo administered on a 1:1 ratio. The study was designed to include 40 male or female outpatients aged 18-70 years. The primary endpoint was the "composite" Clinical Global Impression of Improvement (CGI-I) responder rate, factoring in improvement in both MDD and SAD features. Major secondary outcome measures were changes on the Montgomery Asberg Depression Rating Scale (MADRS) and Liebowitz Social Anxiety Scale (LSAS). RESULTS: On the composite CGI-I, 10 of 20 (50%) vortioxetine and six of 20 (30%) placebo-treated patients were rated as responders, a non-significant difference. However, vortioxetine-treated patients did show significantly greater improvement than those on placebo on both the MADRS (effect size 0.672) and LSAS (effect size 0.714). Efficacy in depression was seen before improvement in SAD. Adverse effects were similar to those previously reported. CONCLUSIONS: In this preliminary trial vortioxetine appears safe and effective for patients with MDD comorbid with SAD, with robust effect sizes on dimensional measures of both depression and social anxiety, but failure to separate from placebo on the primary outcome measure of composite responder rate. More studies of patients with comorbid conditions are needed, as this mirrors what is often seen in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Self-citationBeesdo, K., Bittner, A., Pine, D. S., Stein, M. B., Höfler, M., Lieb, R., & Wittchen, H.-U. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.903 · Cited by 731 · cited 1×
“Moreover, they often occur together; SAD is the most common comorbid anxiety disorder found in individuals with MDD, and individuals with SAD are at increased risk for MDD (Beesdo et al., 2007).”
BackgroundStein, M. B., Fuetsch, M., Müller, N., Höfler, M., Lieb, R., & Wittchen, H.-U. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.3.251 · Cited by 573
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Cited by
Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges
Koyuncu, A., İnce, E., Ertekin, E., & Tükel, R. (2019) · Drugs in Context · doi:10.7573/dic.212573 · Cited by 216
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance
Melaragno, A. J. (2021) · Focus · doi:10.1176/appi.focus.20200048 · Cited by 50
Zhang, X., Luo, Q., Wang, S., Qiu, L., Pan, N., Kuang, W., Lui, S., Huang, X., Yang, X., Kemp, G. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102910 · Cited by 31
“For similar reasons, patients with comorbidities have often been excluded from treatment studies in SAD [111].”
BackgroundPharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Metadata
- Authors
- Liebowitz, M. R., Careri, J., Blatt, K., Draine, A., Morita, J., Moran, M., & Hanover, R.
- Venue
- Depression and Anxiety
- Publisher
- Wiley
- Published
- 2017-11-22
- Volume
- 34
- Issue
- 12
- Pages
- 1164-1172
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W2770687003
- Cited by
- 27
- References
- 4
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.